The FDA has bestowed breakthrough therapy status on an LSD formulation found to relieve symptoms of anxiety and depression with a single dose. Mind Medicine’s MM120 (lysergide d-tartrate) is used to treat generalized anxiety disorder. Twelve weeks after receiving a dose in a Phase 2 trial, 48% of patients were in remission and 65% saw significantly improved symptoms, according to the company. “The clinical improvement for many patients was more than double what we see with today’s standard of care,” MindMed’s chief medical officer, Dr. Daniel Karlin, assistant professor of psychiatry at Tufts …